secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROTHENA CORP PUBLIC LTD CO (PRTA)
CIK:        0001559053
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001559053-24-000034
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prothena reports Q3 net loss of $59M on $1M revenue, cash at $520M; pipeline readouts expected in 2024-2025
--------------------------------------------------------------------------------

- Net loss of $59.0M ($1.10 per share) vs net income of $21.9M ($0.38 diluted) in Q3 2023; revenue fell to $1.0M from $84.9M.
- Cash and restricted cash $520.1M as of Sep 30 2024; full-year net cash use guidance reaffirmed at $148-$160M.
- Expects topline results from Phase 2b PADOVA (prasinezumab) in 4Q2024 and Phase 3 AFFIRM-AL (birtamimab) in 1H2025.
- Phase 1 ASCENT trials (PRX012) for Alzheimer's disease to report multiple readouts starting mid-2025.
- Appointed Chad J. Swanson, Ph.D., as Chief Development Officer in September 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1559053/000155905324000034/0001559053-24-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1559053/000155905324000034/prta-20241112.htm
  HTML page:      https://secwatch.observer/filing/0001559053-24-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer